Yesight Medical Secures Tens of Millions in Series A+ Funding to Accelerate Commercialization of Domestic High-End Widefield SLO Retinal Imaging Devices
Yesight
Ophthalmic Medical Device R&D and Manufacturer
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Centralized Procurement Scaling Up | Ophthalmic Optometry Column
Recently,Yaoshi (Suzhou) Medical Technology Co., LtdAnnouncement CompletedTens of Millions of Yuan in A+ Round Financing，This round of financing was led by YuanHe Pu Hua led the strategic investment, Hai Hong Jin Li followed up, and Multi-Dimensional Capital served as the exclusive financial advisor.The funds raised will be mainly used to accelerate the company's core products.Ultra-Widefield Confocal Laser Scanning Ophthalmoscope (SLO)The marketization of products both in China and internationally, as well as the development of multiple innovative ophthalmic optical devices.
As a company established only five years ago, Yesight has achieved breakthroughs in the SLO (Scanning Laser Ophthalmoscope) field., its first ultra-widefield confocal laser scanning ophthalmoscope was approved for Class II medical device registration in China in 2024 and has entered clinical use in top-tier ophthalmic hospitals in China.
# From Technical Entrepreneurship to Team Collaboration
The story of Yesight did not begin with financing but rather stems from the personal choice of its founder, Wu Haizhou.
As a technology-driven entrepreneur with over 15 years of experience in the medical device field, he has held positions at world-renowned Fortune 500 companies such as Bosch Group, Toyota Tsusho, and Toshiba Group of Japan. He led the development of CT basic control software and imaging algorithms and participated in the underlying software R&D for ophthalmic devices at companies like TOMEY. His extensive cross-border work experience has enabled him to...Medical Imaging and Ophthalmic OpticsSystematic experience has been accumulated in two technical lineages.
In 2018, Wu Haizhou collaborated with a professor from the University of Tokyo and several ophthalmic technology experts to jointly develop the SLO confocal fundus camera and vision screening device. This phase of exploration became the prototype for his future entrepreneurship. In 2020, he chose to return to China to start his business and was selected for the "Leading Entrepreneurship Talent" program in Suzhou New District and Gusu District.
Under his leadership,Yesight has formed a research and development team with a Chinese and Japanese background.The core team members are mostly from the top three ophthalmic equipment companies in Japan and have participated in the research, development, and industrialization of core products such as SLO and OCT.
The company alsoEstablishing a Research Institute in Japan to Form a Cross-Border R&D Collaboration Mechanism. This combination of technology and talent gives it the potential to break into the high-end fundus imaging equipment sector, where there is a significant gap in domestically produced options.
# Key Implementation from R&D to Clinical
In terms of performance, Yetsea 300 has multiple differentiated features:
Ultra-Wide Angle Imaging: A single scan can cover a 168° retinal range, approximately three times that of traditional devices, significantly improving the detection rate of peripheral retinal lesions and reducing the risk of missed diagnoses.
Multi-laser Confocal Scanning: Using red, blue, green, and infrared laser synchronous imaging, it can achieve layered imaging and more clearly display tiny lesions.
Multimodal Fusion: Integrates multiple imaging methods such as color photography, autofluorescence, angiography, and indocyanine green angiography, providing doctors with more diagnostic evidence for complex lesions.
Intelligent Operation: Equipped with automatic positioning and focusing functions, it can complete more than a hundred examinations in a single day, improving the efficiency and turnover rate of medical institutions in fundus examination.
# From Top Hospitals to the International Stage
With the approval of Yetsea 300, Yesight is gradually introducing its product into clinical practice.
Currently, leading ophthalmic centers in China such as Beijing Tongren Hospital, Shenzhen People's Hospital, and Guangzhou Aier Eye Hospital have already taken the lead in applying related technologies. Clinical feedback indicates that this device demonstrates the advantages of ultra-wide-field imaging in detecting peripheral lesions such as diabetic retinopathy, macular degeneration, and retinal detachment.
Doctors generally believe that the application of such devices,Not only improves the sensitivity of lesion detection, but also helps patients receive more precise interventions at an early stage.。
At the market level, Yesight is not limited to China. The companyBuilt"R&D in China + Collaboration with Japan + Global Market Layout"'s composite model. This model is highly aligned with the preferences of the capital market:Not only can it tell the story of "China-made substitution," but it also offers the imaginative space for "global growth."。
As early as 2020, the company reached an exclusive strategic cooperation with a well-known listed technology enterprise in Japan. Later, it also signed a sales framework agreement worth tens of millions of yuan with one of the top three ophthalmology groups in Japan. Through this full-chain linkage of "R&D - registration - clinical - market," Yesight quickly打通了产品出海的路径 and established a preliminary pattern of cross-border cooperation.
From an industry perspective, the popularization of SLO devices represents not only a technological upgrade but also has the potential to drive changes in the screening model for fundus diseases. Traditional examinations often focus on the macular region, whileUltra-Widefield Imaging Incorporates Peripheral Lesions into Daily Diagnosis, which means in the future inDiabetic Retinopathy Screening, Fundus Hemorrhage Risk Monitoring, Age-related Macular Degeneration Follow-upIn scenarios such as these, clinical pathways will become more comprehensive and proactive.
Yaoshi (Suzhou) Medical Technology Co., Ltd. is a high-tech enterprise focused on the research, development, production, and sales of ophthalmic optical equipment. Established in 2020, the company is headquartered in Suzhou. Its flagship product is the ultra-widefield confocal laser scanning ophthalmoscope, which offers advantages such as no need for pupil dilation and clear imaging. In June 2023, the company completed an A-round financing worth tens of millions of yuan, strengthening its capital base and laying the foundation for future growth.
GOC2025
Ophthalmology Solutions Case
Ophthalmic Instruments Industry Research
Statement
Copyright Statement:The original manuscript of "Eye Future" is owned by Beijing Siyu Bot Technology Co., Ltd. Without authorization, it cannot be reproduced, excerpted, or mirrored on other websites, official accounts, or commercial platforms. For reproduction, please contact the backstage to obtain authorization. This platform reserves the right to pursue legal responsibilities for unauthorized full-text reproduction, content rewriting, or adaptation.
